Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|November 11, 1998

ADAC posts record fourth quarter

ADAC Laboratories continues to experience healthy financial growth, thanks to robust performances from all of its businesses. The Milpitas, CA-based nuclear medicine and radiation therapy powerhouse posted a 20% increase in revenue during its record

ADAC Laboratories continues to experience healthy financial growth, thanks to robust performances from all of its businesses. The Milpitas, CA-based nuclear medicine and radiation therapy powerhouse posted a 20% increase in revenue during its record fourth quarter and a 15% revenue increase for its fiscal year.

For the period (end-September), ADAC had record revenues of $86.9 million, compared with the $72.5 million reported in the same period last year. Excluding a one-time restructuring charge, net income was $8.2 million, compared with the $6 million reported last year. With the charge, net income was $3.7 million.

ADAC was also pleased with the progress of its PET business during the quarter. During the period, the company shipped 18 Molecular Coincidence Detection (MCD) units and two C-PET units, compared with 13 MCD units and one C-PET in the prior quarter.

For the fiscal year, ADAC reported revenues of $323.4 million, compared with the $282.3 million reported for the previous fiscal year. Excluding one-time charges, ADAC had net income of $29 million. Including one-time charges, net income for fiscal 1998 was $14.5 million.


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.